Cytori Therapeutics Inc (NASDAQ:CYTX)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $0.34 and last traded at $0.34, with a volume of 535,298 shares changing hands. The stock had previously closed at $0.37.
Several equities analysts recently issued reports on the company. B. Riley restated a “buy” rating and set a $2.30 price target on shares of Cytori Therapeutics in a research note on Monday, May 15th. Zacks Investment Research upgraded Cytori Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 12th. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, August 11th.
The firm’s 50 day moving average price is $0.69 and its 200-day moving average price is $1.16. The company’s market cap is $11.20 million.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.02. The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. Cytori Therapeutics’s quarterly revenue was down 18.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.43) EPS. On average, analysts predict that Cytori Therapeutics Inc will post ($0.60) EPS for the current fiscal year.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 99.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 874,896 shares of the biotechnology company’s stock after buying an additional 435,217 shares during the period. Cytori Therapeutics makes up 1.1% of Perkins Capital Management Inc.’s holdings, making the stock its 28th largest position. Perkins Capital Management Inc. owned 2.69% of Cytori Therapeutics worth $962,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.01% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cytori Therapeutics Inc (CYTX) Sets New 52-Week Low at $0.34” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/08/19/cytori-therapeutics-inc-cytx-hits-new-1-year-low-at-0-34-updated.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.